Ray Resection as a Personalized Surgical Technique for Progressive Hand Macrodactyly in a 60-Year-Old Patient: A Case Report and Literature Review -…

Hand macrodactyly is a very scarce deformity. It was first described over 200 years ago and was characterized as local gigantism of one or multiple digits. Benign bone overgrowth, massive increase of soft tissue volume, and nerve involvement are associated with hand macrodactyly have been consistently reported in the literature. Often, macrodactyly affects one or more digits and is further classified as static or progressive, depending on the growth pattern, and as sporadic or syndromic, according to its genetic predisposition. Surgical treatment for hand macrodactyly remains a complex issue even for expert hand surgeons. In most of the cases, macrodactyly is diagnosed during early childhood and can be appropriately managed with minimal and well affordable surgical approaches that stabilize its fast progression. However, adults with progressive hand macrodactyly develop advanced deformities leading to severe functional deterioration and aesthetic hand dysmorphia. The purpose of this report is to document the management and surgical approach of the oldest published case, a 60-year-old adult patient with neglected progressive hand macrodactyly despite previous surgical attempts for disease stabilization. A personalized preoperative planning was created, which included ray resection involving the fourth metacarpal and fourth finger along with extensive debulking of the overgrown fatty soft tissue and carpal tunnel release. At six months follow-up, the patient reported an excellent aesthetic and functional outcome.

The term macrodactyly is a descriptive term derived from the Greek words macro meaning long and dactyl meaning finger. Macrodactyly of the hand represents a very rare congenital deformity of unknown etiology, which constitutes less than 1% of congenital disorders in the upper extremity [1]. To our knowledge, hand macrodactyly affects approximately 1 out of 100,000 live births and can appear either as a sporadic (isolated form) or as part of a hereditary deformity syndrome (syndromic form) [2]. There are two distinct types of macrodactyly depending on the functional status of the hand. Static macrodactyly is the first type of macrodactyly, with affected fingers being roughly one and a half times the size compared to a normal finger [3]. Besides, static macrodactyly is present at birth and abnormal fingers grow in line with normal fingers [3]. Progressive macrodactyly constitutes the second type, causing continuous bony overgrowth even after skeletal maturity, with digits growing at a much faster rate compared to normal ones [3]. Oftentimes, the dysmorphic appearance of hand macrodactyly causes functional disability in the majority of cases along with cultural stigma, which might have a negative psychological impact on the patient [4].

A plethora of surgical interventions have been described mainly in young patients to cure static and prevent progressive hand macrodactyly, such as debulking procedures, epiphysiodesis, and osteotomies [1]. The purpose of this report is to document the personalized strategy for surgical reconstruction of a neglected progressive hand macrodactyly in an elder 60-year-old male patient - the oldest individual that we are aware of to have been surgically treated based on our literature search - and our efforts to obtain a functional hand with a good aesthetic outcome.

A 60-year-old male individual was presented to our department to seek consultation for his hand macrodactyly. The patients condition was diagnosed in early childhood as a sporadic isolated anomaly affecting moderately the middle and severely the ring fingers. According to his medical records, he underwent two minimal soft tissue debulking surgeries on the third interdigital space when he was 4 and 37 years old, respectively. Initially, he reported that his hypertrophic left middle and ring fingers became more painful and less functional recently, albeit he could manage it until then. The thumb, index, and little fingers were normal. Despite his hand deformity, the patient has been a professional guitar player for at least 40 years. During the last three years, he was complaining of progressive disproportionate growth of his middle and ring fingers (Figure 1). He was further experiencing numbness, tingling, and ache at the tip of all his left digits accompanied with a painful sensation of fullness on the affected fingers. Phalens test was positive, and electrophysiological tests were indicative of carpal tunnel syndrome due to median nerve compression. However, the ulnar nerve was not found entrapped through Guyon's canal. Likewise, the movements of middle and ring fingers were extremely restricted due to soft tissue hypertrophy and stiffness of his metacarpophalangeal and interphalangeal joints. The flexion of his two gigantic fingers was severely deteriorated due to malalignment of joints and angled phalanges. X-rays revealed excessive hand osteoarthritis with the presence of large bone spurs (osteophytes) and joint space narrowing between all phalanges of the third and fourth fingers. Therefore, a debulking reconstruction surgery of the overgrown fatty tissue and ray resection of the most enlarged fourth finger were performed along with carpal tunnel release.

Under axillary block anesthesia and application of a pneumatic tourniquet, a racket-shaped incision was made around the base of the fourth metacarpal. The extensor and flexor tendons (flexor digitorum superficialis and flexor digitorum profundus) as well as interosseous and lumbrical muscles of the fourth finger were detached and transected carefully to prevent tendon injuries of the remaining normal digits. Exposure of the digital neurovascular bundle of the third and fifth fingers was well visualized, mobilized, and preserved. Radial and ulnar digital nerves of the fourth finger were found enlarged and were easily recognized due to their increased thickness. Subsequently, nerve endings were carefully implanted within the surrounding soft tissue to avoid as much as possible the formation of painful neuromas. With a surgical oscillating saw, a transection at the base of the fourth metacarpal was performed. Subsequently, surgical debulking of the extensive soft tissue was implemented (Figure 2), and hemostasis of blood vessels leakage was achieved with an electrocautery. Eventually, median nerve decompression was achieved with a palmar incision to divide the transverse carpal ligament. The surgical procedure was performed by a senior consultant hand surgeon and a hand fellow orthopaedic surgeon. The postoperative plan consisted of temporary splinting and early supervised physiotherapy.

Postoperatively, the patient was complaining of phantom pain, which was well tolerated with a two-week prescription of acetaminophen and NSAIDs. Eventually, the phantom pain was resolved entirely eight weeks after surgery [5]. At the six-month follow-up, the patient reported a great recovery with excellent functional and aesthetic satisfaction (Figure 2). His grip strength and hand mobility improved with at least 30 of better flexion range for third metacarpophalangeal joint and so did abduction-adduction for his index, ring, and small fingers.

Until recently, pathogenesis of osseous and fibrofatty overgrowth in hand macrodactyly is not clearly identified and still no consensus exists on its treatment. Therefore, hand macrodactyly poses a significant surgical challenge. which often requires the expertise of experienced hand surgeons to manage effectively [6].

It has been reported that significant nerve enlargement is usually observed during surgical approach of affected digits with morphological and neurophysiological impairment of the median nerve that requires carpal tunnel release [7]. In the present case, the third and fourth rays were affected with simultaneous enlargement of the radial and ulnar digital nerve of the fourth finger. However, electrophysiological testing depicted entrapment of the median nerve but not of the ulnar nerve. Lipomatosis of peripheral nerves (fibrolipomatous proliferation within the nerve) accompanied with osseous enlargement and hypertrophic changes on osteochondral tissue leads not only to compressive neuropathy but also to disabling ankylosis of innervated joints [8].

Genetic studies have demonstrated that hand macrodactyly can be a clinical manifestation of three major overgrowth syndromes: the Proteus syndrome (mosaic mutations in the AKT1 gene), the PIK3CA-related overgrowth syndrome (mutations in the PIK3CA oncogene), and the PTEN hamartoma tumor syndrome (mutations in somatic PTEN tumor suppressor gene). According to Cui et al., somatic mutations in PIK3CA oncogene were observed within bone marrow stem cells from patients diagnosed with hand macrodactyly [9]. These specific mutations enhance activation of the PI3K/AKT/mTOR pathway and deregulate bone homeostasis, leading to hyperplastic bone formation [9]. Moreover, Cui et al. demonstrated that downregulation of distal-less homeobox 5 gene (DLX5) which induces Runx2-mediated osteogenesis and P13K-mediated bone overgrowth could be inhibited by the administration of BYL719 [9]. Subsequently, the administration of this novel therapeutic agent in early-stage disease could appropriately reverse progressive hand macrodactyly [9].

Progressive macrodactyly is an extremely challenging disease as no surgery is able to cure the underlying condition. Most patients, even if operated early in life, require multiple debulking procedures in accordance with the present case report. Concurring to the literature, only few published reports demonstrate potential strategies and surgical treatment options for progressive hand macrodactyly without a clear consensus on treatment guidelines, as shown in Table 1 [5,10]. Children with static hand macrodactyly can be appropriately treated with minimal surgical interventions such as stripping or resection of the local nerve, debulking, closing-wedge osteotomies, and phalangeal epiphysiodesis [10,11]. A very innovative surgical technique was proposed by Kobraei et al. to prevent fast skeletal overgrowth and avoid digits amputation in progressive hand macrodactyly [12]. According to the authors, a radical dissection of the diseased gross digital nerve in two cases with thumb (radial digital nerve) and ring finger (ulnar digital nerve) overgrowth was performed until healthy nerve stump was found [12]. The gaps were reconstructed with a processed nerve allograft between normal edges [12]. To authors view, an early application of this novel surgical approach could yield functional and aesthetic digits with remarkable sensory outcomes and significant deceleration of the disease [12].

The largest case series study considering clinical characteristics and surgical management of 90 hand macrodactyly cases was conducted by Wu et al. [2]. According to their study, multiple digit involvement is up to 2.6 times more frequent than a single-digit disease, which is in line with our patient who had his middle and ring fingers enlarged. In the case series report by Wu et al., most of the affected digits (79.4%) involved were in the median nerve innervation surface [2]. However, in the present case report, the patient had a ring finger macrodactyly, which corresponds to the ulnar nerve area, with no signs of ulnar nerve compression. In addition, the study by Wu et al. included young patients aged between six months and five years. The vast majority of patients were treated with soft tissue reconstruction or minimal phalangeal osteotomies and only two out of 90 cases had an amputation [2]. Consequently, function-preserving surgeries are performed instead of amputation when hand macrodactyly is effectively treated during early-stage compared to advanced-stage disease.

Based on recent bibliography, Jacobs et al. presented the most advanced case of a 55-year-old female patient diagnosed with Proteus syndrome and macrodactyly of her right-hand thumb, middle, and index fingers [5]. The individualized surgical plan included amputation of the thumb and index rami and removal of trapezoid, trapezium, and scaphoid bones [5]. Consequently, the resulted wrist instability was treated with transosseous ligament reconstruction [5]. Good aesthetic and functional results were comparable to that in our patient who was treated with a lesser ray resection technique. To the best of our knowledge, the present case report depicts the surgical management of the oldest patient (60-year-old male) with progressive isolated macrodactyly among the published cases in recent literature. In addition, we strongly believe that efficient stabilization during early-stage disease would have prevented the development of severe chronic osteoarthritis in the metacarpophalangeal, proximal interphalangeal, and distal interphalangeal joints of the third and fourth fingers, which add more disability to a macrodactyly hand.

Hand macrodactyly is usually visible at birth and patients experience overgrowth symptoms during early childhood. Consequently, an early and effective surgical management is strongly recommended to prevent chronic progression and development of severe secondary degenerative bone changes in macrodactyly fingers, such as ankyloses, narrowing of joints, and formation of osteophytes. Patients suffering from hand macrodactyly can significantly benefit from early surgical stabilization of the condition instead of late and more aggressive interventions such as amputation.

In the present case, surgical interventions at an early stage proved ineffective, and the patient developed severe and disabling hand deformities due to the progressive subtype of hand macrodactyly. Most of the macrodactyly cases seem to stabilize at skeletal maturity, and it is unusual to see this degree of progressive bony overgrowth. Nevertheless, a personalized surgical technique including ray resection and debulking reconstruction surgery was proposed for this neglected case with great aesthetic and functional outcomes.

More here:
Ray Resection as a Personalized Surgical Technique for Progressive Hand Macrodactyly in a 60-Year-Old Patient: A Case Report and Literature Review -...

Cell Therapy Market is Expected to Grow by USD 20.2 Billion Progressing at a CAGR of 14.5% By Forecast 2027 – Digital Journal

TheGlobal Cell Therapy Marketwas worth USD7.8 billion in 2021, according to a new analysis released by Maximize Market Research, and is expected to rise to USD 20.2 billion by 2027, with a CAGR of 14.5% percent over the forecast period. From the markets perspective, its ever-changing trends, industrial environment, existing market features, and the current short-term and long-term influence on the market

the research will aid decision-makers in developing the outline and strategies for organisations by region.

The implantation of a human cell to replace or repair damaged tissue or cells is known as cellular therapy. Therapy typically consists of live cells that are safely injected, implanted, or grafted into the patients body to have a therapeutic effect. T-cell and stem cell treatment are two types of cell therapy that are used to combat cancer via cell mediated immunity or to repair damaged tissues. For patients with long-term ailments, cell therapy has become a popular treatment option.

Cell Therapy Market Scope and Dynamics:

The Maximize Market Research report contains a detailed study of factors that will drive and restrain the growth of the Cell Therapy Market Globally. Significant advances in cell therapy, a growing emphasis on regenerative medicine, increased R&D activities in the life sciences sector to develop advanced cellular therapies, and the rising prevalence of cancer, musculoskeletal disorders, cardiovascular diseases, autoimmune disorders, and neurological diseases are all driving the global cell therapy market revenue growth.

Other significant factors driving global market revenue growth include increased awareness and commercialization of stem cell therapies, an increase in the number of clinical trials of new cell therapies, an increase in the use of human cells in cell therapy research and development, and an increase in cellular therapy manufacturing under Good Manufacturing Practices (GMP) supervision. Increased government investments in the healthcare industry, as well as increased collaborations between pharmaceutical and biotechnology behemoths and leading research institutes for the development of advanced cellular therapies for cancer, cardiovascular disease, and other severe chronic diseases, are expected to boost global cell therapy market revenue growth in the coming years.

The Impact of COVID-19 on the Cell Therapy Market:

The COVID-19 pandemic has impacted the majority of biopharmaceutical companies, but several cellular treatment development companies have seen a significant negative impact, which can be related to logistical issues as well as the manufacturing models used in this field. Furthermore, large and reliable funding is required to ensure successful commercial translation of cell-based medicines, a factor that was negatively impacted in 2020, affecting market growth even more.

Request For Free Sample @https://www.maximizemarketresearch.com/request-sample/126471

Cell Therapy Market Region Insights:

Regional analysis is another highly comprehensive part of the research and analysis study of the global Cell Therapy Market presented in the report. The global cell treatment market is dominated by North America. In 2020, North America held a total market share of 14.5%percent, as new institutions and institutes invest in R&D to propel cell therapy forward. Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Harvard Stem Cell Institute, and Yale Steam Cell Center are among the main universities in the United States that are involved in new research in cell regenerative technologies. During the forecasted period, Asia Pacific is expected to increase at a significant rate of 14.5%percent. China, South Korea, and Japan are spending extensively in regenerative medicine and stem cell therapies. Certain government-funded institutes are devoted to R&D with the goal of pushing the market forward.

What does the report include?

The study on the Global Cell Therapy Market includes qualitative characteristics such as drivers, constraints, and opportunities . The research looks at the current and future rivals in the Global Cell Therapy Market, as well as their product development strategies. The study examines the market in both qualitative and quantitative terms, and it is separated into three segments: component, deployment type, organisation size, and industry. Furthermore, the report provides comparable statistics for the key regions. For each of the above-mentioned segments, actual market sizes and predictions have been presented.

Cell Therapy Market Segmentation:

Global Cell Therapy Market, by Therapy Type:

Autologous Allogeneic

Global Cell Therapy Market, by Cell Type:

T-Cell Stem Cell

Global Cell Therapy Market, by Application:

Malignancies Musculoskeletal Disorder Autoimmune Disorder Dermatology Others

Global Cell Therapy Market, by End User:

Hospitals and clinics Academics and Research Institutes

By Region:

North America Europe Asia Pacific South America Middle East and Africa

Key Players in Cell Therapy Market:

Kolon TissueGene Inc. Anterogen Co. Ltd. JCR Pharmaceuticals Co., Ltd. Castle Creek Biosciences, Inc. The Future of Biotechnology, MEDIPOST Osiris Therapeutics, Inc. PHARMICELL Co., Ltd Tameika Cell Technologies, Inc. Cells for Cells NuVasive, Inc. Vericel Corporation Celgene Corporation Thermo Fisher Scientific Inc. Merck KGaA Danaher Corporation Becton, Dickinson, and Company Lonza Group Sartorius AG Terumo BCT Fresenius Medical Care AG & Co. KGaA

To Get a Detailed Report Summary and Research Scope of Cell Therapy MarketClick here @https://www.maximizemarketresearch.com/market-report/cell-therapy-market/126471/

About Maximize Market Research:

Maximize Market Research, a global market study firm with a dedicated team of specialists and data, has conducted thorough research on the Cell Therapy Market. Maximize Market Research is well-positioned to assess and predict market size while also taking into account the competitive landscape of the various industries. Maximize Market Research has a strong unified team of industry professionals and analysts across sectors to guarantee that the whole industry ecosystem, as well as current developments, new trends, and futuristic the technology effect of uniquely particular industries is taken into consideration.

Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

[emailprotected]

Read the original:
Cell Therapy Market is Expected to Grow by USD 20.2 Billion Progressing at a CAGR of 14.5% By Forecast 2027 - Digital Journal

Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team – BioSpace

REDWOOD CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) --Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced changes to its management team, including the promotions of Jeet Mahal to the newly created position of Chief Operating Officer, and of Wendy Pang, M.D., Ph.D., to Senior Vice President of Research and Translational Medicine. Both promotions are effective as of March 21, 2022. Jasper also announced that a new position of Chief Medical Officer has been created, for which an active search is underway. Judith Shizuru, M.D. PhD, co-founder, and Scientific Advisory Board Chairwoman will lead clinical development activities on an interim basis and Kevin Heller, M.D., EVP of Research and Development, will be transitioning to a consultant role.

Based on the recent progress with JSP191, our anti-CD117 monoclonal antibody, as a targeted non-toxic conditioning agent and our mRNA hematopoietic stem cell program we have decided to advance Jaspers organizational structure with the creation of the roles of Chief Operating Officer and Chief Medical Officer and by elevating our research and translational medicine team to report directly to the CEO, said Ronald Martell, CEO of Jasper Therapeutics. We also are pleased that Dr. Shizuru will lead clinical development activities on an interim basis, a role she served during the companys founding in 2019.

These changes will allow us to advance our upcoming pivotal trial of JSP191 in AML/ MDS and execute on our pipeline opportunities with a best-in-class organization, continued Mr. Martell. We also wish to thank Dr. Heller for his help advancing JSP191 through our initial AML/MDS transplant study.

In the two plus years since we founded Jasper and received our initial funding, the company has been able to advance JSP191 in two clinical studies, develop our mRNA stem cell graft platform and publicly list on NASDAQ, said Dr. Shizuru, co-founder and member of the Board of Directors of Jasper Therapeutics. These changes will strengthen the companys ability to advance the field of hematopoietic stem cell therapies and bring cures to patients with hematologic cancers, autoimmune diseases and debilitating genetic diseases."

Mr. Mahal joined Jasper in 2019 as Chief Finance and Business Officer and has led Finance, Business Development, Marketing and Facilities/ IT since the companys inception. Prior to joining Jasper, he was Vice President, Business Development and Vice President, Strategic Marketing at Portola Pharmaceuticals, where he led the successful execution of multiple business development partnerships for Andexxa, Bevyxxaand cerdulatinib. He also played a key role in the companys equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the Xareltodevelopment and strategic marketing team. Mr. Mahal holds a BA in Molecular and Cell Biology from U.C. Berkeley, a Masters in Molecular and Cell Biology from the Illinois Institute of Technology, a Masters in Engineering from North Carolina State University and an MBA from Duke University.

Dr. Pang joined Jasper in 2020 and has led early research and development including leading creation of the companys mRNA stem cell graft platform and playing a pivotal role in advancing JSP191 across multiple clinical studies. Previously Dr. Pang was an Instructor in the Division of Blood and Marrow Transplantation at Stanford University and the lead scientist in the preclinical drug development of an anti-CD117 antibody program. She was the lead author on the proof-of-concept studies showing that an anti-CD117 antibody therapy targets disease-initiating human hematopoietic (blood cell-forming) stem cells in myelodysplastic syndrome (MDS). She has authored numerous publications on the characterization of hematopoietic stem and progenitor cell behavior in hematopoieticdiseases, as well as hematopoietic malignancies, including MDS and acute myeloid leukemia (AML), and in hematopoietic stem cell transplantation. Dr. Pang earned her AB and BM in Biology from Harvard University and her MD and PhD in cancer biology from Stanford University.

Dr. Shizuru is a Professor of Medicine (Blood and Marrow Transplantation) and Pediatrics (Stem Cell Transplantation) at StanfordUniversity.She is the clinician-scientist co-founder of Jasper Therapeutics. Dr. Shizuru is an internationally recognized expert on the basic biology of blood stem cell transplantation and the translation of this biology to clinical protocols.Dr Shizuruis a member of the Stanford Blood and Marrow Transplantation (BMT) faculty, the Stanford Immunology Program, and the Institute for Stem Cell Biology and Regenerative Medicine. Shehas been an attending clinicianattendedon the BMT clinical service since 1997.Currently, she oversees a research laboratory focused on understanding the cellular and molecular basis of resistance to engraftment of transplantedallogeneic bone marrow blood stemcells and the way in which bone marrow grafts modify immune responses.Dr. Shizuru earned her BA from Bennington College and her MD and PhD in immunology from Stanford University

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. Jasper is also advancing JSP191 as a potential therapeutic for patients with lower risk Myelodysplastic Syndrome (MDS). Jasper Therapeutics is also advancing its preclinical mRNA hematopoietic stem cell graft platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would,plan,predict,potential,seem,seek,future,outlookandsimilarexpressionsthat predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potentialof the Companys JSP191 and mRNA engineered stem cell graft programs. Thesestatementsarebasedonvariousassumptions,whetherornotidentifiedinthispressrelease, and on the current expectations of Jasper and are not predictions of actual performance. These forward-lookingstatementsareprovidedforillustrativepurposesonlyandarenotintendedtoserve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitivestatementoffactorprobability.Actualeventsandcircumstancesaredifficultorimpossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jaspers product candidates; the risk that prior study results may not be replicated; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jaspers product candidates may not be beneficialtopatientsorsuccessfullycommercialized;patientswillingnesstotrynewtherapiesand the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk thatJaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection foritsinvestigationalproductsorwillinfringetheintellectualpropertyprotectionofothers;andother risks and uncertainties indicated from time to time in Jaspers filings with the SEC. If any of these risksmaterializeorJaspersassumptionsproveincorrect,actualresultscoulddiffermateriallyfrom the results implied by these forward-looking statements. While Jasper may elect to update these forward-lookingstatementsatsomepointinthefuture,Jasperspecificallydisclaimsanyobligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessmentsofanydatesubsequenttothedateofthispressrelease.Accordingly,unduereliance should not be placed upon the forward-lookingstatements.

Contacts:

John Mullaly (investors) LifeSci Advisors 617-429-3548 jmullaly@lifesciadvisors.com

Jeet Mahal (investors) Jasper Therapeutics 650-549-1403 jmahal@jaspertherapeutics.com

Originally posted here:
Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team - BioSpace

Stem Cell Assay Market Size And Forecast | Top Key Players Thermo Fisher Scientific, Perkinelmer, Stemcell Technologies, Merck, Bio-Rad Laboratories,…

New Jersey, United States,-The latest research report provides a complete assessment of theStem Cell AssayMarketfor the forecast year 2022-2029, which is beneficial for businesses regardless of their size and revenue. This survey report covers the key market insights and industry approach related to COVID-19 (Omicron) in the coming years. TheStem Cell Assaymarket report provides data and information on the development of the investment structure, technological improvements, market trends and developments, capabilities, and in-depth information on the major players of theStem Cell Assaymarket. The market strategies followed worldwide in relation to the current and future scenario of the industry have also been detailed in the study.

The report begins with a brief presentation and overview of theStem Cell Assaymarket, the current market landscape, market trends, key market players, product type, application, and region. It also covers the impact of COVID-19 (Omicron) on theStem Cell AssayMarket Trends, Future Forecast, Growth Opportunities, End-User Industries, and Market Players. It also provides historical data, current market scenarios, and future insights into the Stem Cell Assaymarket. This study provides a comprehensive understanding of market value with the product price, demand, gross margin, and supply of theStem Cell Assaymarket. The Competitive Perspective section of the report provides a clear insight into the market share analysis of the major players in the industry.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=24266

Key Players Mentioned in the Stem Cell Assay Market Research Report:

Thermo Fisher Scientific, Perkinelmer, Stemcell Technologies, Merck, Bio-Rad Laboratories, Agilent Technologies

The Stem Cell Assay market is segmented by product and type. All of these segments were examined individually. The detailed study helps to evaluate the factors affecting the Stem Cell Assay market. Experts analyzed the nature of development, investments in research and development, changing consumption patterns, and the growing number of applications. Furthermore, analysts have also assessed the development of the economy around the Stem Cell Assay market which is likely to impact its price.

Stem Cell AssayMarket Segmentation:

Stem Cell Assay Market by Product

Reagents and Kits Instruments

Stem Cell Assay Market by Application

Regenerative Medicine and Therapy Clinical Research Drug Discovery and Development

Stem Cell Assay Market by Assay

Cell Identification Assays Viability or Cytotoxicity Assays Apoptosis Assays Isolation & Purification Assays Others

The regional analysis section of the report allows players to focus on high-growth regions and countries that could help them to expand their presence in the Stem Cell Assay market. Besides expanding their presence in the Stem Cell Assay market, regional analysis helps players increase sales while gaining a better understanding of customer behavior in specific regions and countries. The report provides CAGR, revenue, production, consumption, and other important statistics and figures on global and regional markets. It demonstrates how different types, applications, and regional segments of the Stem Cell Assay market are progressing in terms of growth.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24266

Stem Cell Assay Market Report Scope

Determining the pulse of the market becomes easy through this in-detail Stem Cell Assay market analysis. Key players can find all competitive data and market size of major regions like North America, Europe, Latin America, Asia-Pacific and Middle East. As part of the competitive analysis, certain strategies are profiled which are pursued by key players such as mergers, collaborations, acquisitions and new product launches. These strategies will greatly help industry players to strengthen their market position and grow their business.

Key questions answered in the report:

1. Which are the five top players of the Stem Cell Assay market?

2. How will the Stem Cell Assay market change in the next five years?

3. Which product and application will take a lions share of the Stem Cell Assay market?

4. What are the drivers and restraints of the Stem Cell Assay market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Stem Cell Assay market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/stem-cell-assay-market/

Visualize Stem Cell Assay Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Stem Cell Assay Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

Here is the original post:
Stem Cell Assay Market Size And Forecast | Top Key Players Thermo Fisher Scientific, Perkinelmer, Stemcell Technologies, Merck, Bio-Rad Laboratories,...

Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates – BioSpace

Plans to present data at multiple scientific conferences in 2022

Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022

2021 year-end cash position of $746.9 million

SEATTLE, March 16, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2021.

We are pleased with the progress we are making in our pipeline and in building capabilities to execute our vision of exploiting the potential of engineered cells to treat a number of diseases that dont have effective treatments today, said Steve Harr, Sanas President and Chief Executive Officer. In 2021, we meaningfully strengthened our balance sheet, advanced our pipeline giving us the potential for two investigational new drug applications (INDs) in 2022 and multiple INDs per year going forward, built out our supply chain, including commercial access to gene-editing reagents and pluripotent stem cells, and commenced the build-out of our own manufacturing facility. Most importantly, we successfully attracted talent in key business areas, which, combined with the people already inside of the company, give us the capabilities, insights, focus, and dedication to reach our mission for patients.

Recent Corporate Highlights

Demonstrating forward progress in moving toward clinical trials for Sanas multiple platforms including Sanas ex vivo hypoimmune allogeneic CAR T, in vivo fusogen CAR T, and stem cell-derived programs:

Strengthened balance sheet and Board leadership; signed lease to add internal manufacturing capability

Fourth Quarter 2021 Financial Results

GAAP Results

Non-GAAP Measures

A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under Non-GAAP Financial Measures.

About Sana

Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 380 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements about Sana Biotechnology, Inc. (the Company, we, us, or our) within the meaning of the federal securities laws, including those related to the companys vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; the potential use and utility of licensed technologies for Sanas programs; the potential ability to make hypoimmune-modified iPSCs that survive and evade the immune system without immunosuppression; the potential ability to make hypoimmune allogeneic CAR T cells that evade the immune system; the potential efficacy of CD19-targeted hypoimmune CAR T cells; the potential efficacy of a CD8 targeted fusosome containing a CD20-targeted CAR and of Sanas SG295 program; the potential efficacy of the NIHs CAR construct; the potential benefits of targeting both CD19 and CD22 with an off-the-shelf product, including in combination with Sanas hypoimmune or fusogen platform; the ability to make stem cell-derived pancreatic islet cells and hypoimmune pancreatic islet cells, and the function and efficacy of such cells; and the potential ability to eliminate engraftment arrythmias in hypoimmune-modified pluripotent cell-derived cardiomyocytes. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Companys strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as aim, anticipate, assume, believe, contemplate, continue, could, design, due, estimate, expect, goal, intend, may, objective, plan, positioned, potential, predict, seek, should, target, will, would and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Companys current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Companys actual results, please refer to the risk factors identified in the Companys SEC reports, including but not limited to its Annual Report on Form 10-K dated March 16, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Investor Relations & Media: Nicole Keith investor.relations@sana.com media@sana.com

Sana Biotechnology, Inc. Unaudited Selected Consolidated Balance Sheet Data

Sana Biotechnology, Inc. Unaudited Consolidated Statements of Operations

Sana Biotechnology, Inc. Changes in the Estimated Fair Value of Success Payments and Contingent Consideration

(1) Cobalt Biomedicine, Inc. (Cobalt) and the Presidents of Harvard College (Harvard) are entitled to success payments pursuant to the terms of their agreements. The success payments are recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations. (2) Cobalt is entitled to contingent consideration upon the achievement of certain milestones pursuant to the terms of the agreement. Contingent consideration is recorded at fair value and remeasured at each reporting period with changes in the estimated fair value recorded in research and development related success payments and contingent consideration on the statement of operations.

Non-GAAP Financial Measures

To supplement the financial results presented in accordance with generally accepted accounting principles in the United States (GAAP), Sana uses certain non-GAAP financial measures to evaluate its business. Sanas management believes that these non-GAAP financial measures are helpful in understanding Sanas financial performance and potential future results, as well as providing comparability to peer companies and period over period. In particular, Sanas management utilizes non-GAAP operating cash burn, non-GAAP research and development expense and non-GAAP net loss and net loss per share. Sana believes the presentation of these non-GAAP measures provides management and investors greater visibility into the Companys ongoing actual costs to operate its business, including actual research and development costs unaffected by non-cash valuation changes and certain one-time expenses for acquiring technology, as well as facilitating a more meaningful comparison of period-to-period activity. Sana excludes these items because they are highly variable from period to period and, in respect of the non-cash expenses, provides investors with insight into the actual cash investment in the development of its therapeutic programs and platform technologies.

These are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with Sanas financial statements prepared in accordance with GAAP. These non-GAAP measures differ from GAAP measures with the same captions, may be different from non-GAAP financial measures with the same or similar captions that are used by other companies, and do not reflect a comprehensive system of accounting. Sanas management uses these supplemental non-GAAP financial measures internally to understand, manage, and evaluate Sanas business and make operating decisions. In addition, Sanas management believes that the presentation of these non-GAAP financial measures is useful to investors because they enhance the ability of investors to compare Sanas results from period to period and allows for greater transparency with respect to key financial metrics Sana uses in making operating decisions. The following are reconciliations of GAAP to non-GAAP financial measures:

Sana Biotechnology, Inc. Unaudited Reconciliation of Change in Cash, Cash Equivalents, and Marketable Securities to Non-GAAP Operating Cash Burn

(1) The non-GAAP adjustment of $52.1 million for the twelve months ended December 31, 2021 consisted of the one-time upfront payment of $50.0 million to Beam to license its genome editing technology and holdback payments of $2.1 million related to the acquisitions of Cytocardia, Inc. in 2019 and Oscine Corp. in 2020. The non-GAAP adjustment of $7.7 million for the twelve months ended December 31, 2020 was the upfront payment related to the acquisition of Oscine Corp. in 2020. (2) The non-GAAP adjustment of $6.0 million for the twelve months ended December 31, 2020 was the payment of a contingent liability due to Harvard in connection with the closing of the Series B convertible preferred stock financing.

Sana Biotechnology, Inc. Unaudited Reconciliation of GAAP to Non-GAAP Research and Development Expense

(1) The non-GAAP adjustment of $8.5 million for the twelve months ended December 31, 2020 was the upfront expense recorded in connection with the acquisition of Oscine Corp. in 2020. (2) The contingent liability was recorded in connection with the Harvard license agreement and paid in June 2020.

Sana Biotechnology, Inc. Unaudited Reconciliation of GAAP to Non-GAAP Net Loss and Net Loss Per Share

(1) The non-GAAP adjustment of $8.5 million for the twelve months ended December 31, 2020 was the upfront expense recorded in connection with the acquisition of Oscine Corp. in 2020. (2) For the three and twelve months ended December 31, 2021, we recorded a gain related to the Cobalt success payment liability of $23.3 million and an expense of $23.6 million, respectively. For the three and twelve months ended December 31, 2020, we recorded expenses related to the Cobalt success payment liability of $27.1 million and $62.3 million, respectively. For the three and twelve months ended December 31, 2021, we recorded a gain related to the Harvard success payment liability of $8.4 million and an expense of $2.4 million, respectively. For the three and twelve months ended December 31, 2020, we recorded expenses related to the Harvard success payment liability of $4.4 million and $9.9 million, respectively. The expense and gain recorded in each period are due to changes in our market capitalization and common stock price during the relative periods. (3) The contingent consideration was recorded in connection with the acquisition of Cobalt. The change in value of the contingent consideration was primarily due to scientific progress toward the achievement of milestones during the relative periods. (4) The contingent liability was recorded in connection with the Harvard license agreement and paid in June 2020.

See more here:
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates - BioSpace

Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL – AJMC.com Managed Markets Network

Mantle cell lymphoma is a difficult cancer type with high relapse rates, but novel targeted approaches such as CAR T-cell therapy hold promise for more successful response rates in the future.

First-line treatment strategies for mantle cell lymphoma (MCL) currently range from intensive chemotherapy and autologous stem cell transplant (ASCT) to combination regimens and novel targeted therapies. As chimeric antigen receptor (CAR) T-cell therapies change the treatment landscape in other hematological cancer types, a recent review sees potential for this novel strategy to improve outcomes for MCL.

MCL is a B-cell malignancy that is rare and challenging to treat, and relapse rates are high. In most cases of MCL, the chromosomal translocation t(11;14) causes overexpression of thecyclin D1 (CCND1) gene, although other mechanisms are also involved. Despite progress in identifying the pathogenesis and risk factors of MCL, there are still no curative treatments for it.

In the first-line setting, the current standard treatment for otherwise healthy younger patients is intensive immunochemotherapy, potentially followed by ASCT to improve response duration. Older patients who cannot tolerate intensive treatment typically undergo treatment with more tolerable combination regimens.

When patients relapse, targeted agents are generally used in lieu of the chemoimmunotherapy seen in first-line treatment. Initially, bortezomib, temsirolimus, and lenalidomide were the only approved targeted second-line treatments, but the current treatment landscape also includes agents such as Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors, lenalidomide, and venetoclax. Three BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib are currently approved for relapsed or refractory MCL.

Response rates have been promising with targeted therapies, but response durations are often limitedand even on these regimens, many patients relapse. In patients with known risk factors such as TP53aberrations, high Ki-67, or those whose disease progresses on BTK inhibition, treatment is even more challenging and novel approaches must be identified to improve outcomes.

In recent years, CAR T-cell therapy has emerged as a promising treatment option in hematological cancers, including B-cell lymphomas. Four CAR T-cell therapies targeting CD19 are currently approved for B-cell lymphomas: axicabtagene ciloleucel (axi-cel) is approved for diffuse large B-cell lymphoma (DLBCL) in the third-line setting, tisagenlecleucel (tisa-cel) is approved for relapsed and refractory DLBCL, lisocabtagene maraleucel (liso-cel) is approved for DLBCL, and brexucabtagene autoleucel (brexu-cel) is approved for relapsed or refractory MCL.

While research on CAR T-cell therapy is limited in MCL compared with other types of cancer, the review authors highlight 2 trials of brexu-cel and liso-cel in relapsed and refractory MCL.

In the phase 2 ZUMA-2 trial (NCT02601313) of brexu-cel, the first multicenter trial of CAR T-cell therapy in relapsed and refractory MCL, patients who had received 2 or more lines of therapy prior to brexu-cel were given a single infusion. It was highly active in the cohort used for efficacy analysis, with a 93% overall response rate (ORR) and 67% of patients achieving complete response (CR). In the overall cohort of 74 patients, the ORR was 85%, and 59% of patients achieved CR. At 17.5 months of follow-up, 48% of patients remained in response. Hematological toxicity was the most common adverse event (AE), with 94% of patients experiencing grade 3 or higher toxicity.

The TRANSCEND NHL 001 study (NCT02631044) of liso-cell included multiple types of lymphoma. In 32 patients who were infused with liso-cel, the ORR was 84%, and 59% of patients achieved CR. The most common grade 3 or greater AEs were hematologic toxicities, which affected 34% of patients.

In the future, different combinations and novel agents such as second-generation BTK inhibitors that are currently in development may produce more favorable results for patients with MCL. Determining proper sequencing for combination therapies and the best ways to use CAR T-cell therapy are also important factors, the authors noted.

While there has been progress in MCL research and treatment development, it still remains incurable, and the authors point to novel targeted agents and potential combinations with CAR T-cell therapies as likely future routes for progress.

Reference

Tbakhi B, Reagan PM. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).Ther Adv Hematol. Published online February 26, 2022. doi:10.1177/20406207221080738

Read more here:
Current Strategies and the Potential of CAR T-Cell Therapy in Relapsed and Refractory MCL - AJMC.com Managed Markets Network

Cortexyme, SQZ, Others Present New Insights into Alzheimer’s and Parkinson’s – BioSpace

The 2022 International Conference on Alzheimers and Parkinsons Disease held virtually and in Spain late last week and this weekend has ended, but it reported on numerous research studies and insights into the diseases. Heres a look at just a few of those stories.

Cortexyme Offered New GAIN Trial Data on Moderate Alzheimers

Cortexymepresented new data from its Phase II/III GAIN trial of COR388 (atuzaginstat) to treat mild to moderate Alzheimers disease. The data described target engagement data showing the drug inhibited lysine gingipains, which demonstrated a 30% to 50% slowing in cognitive decline in participants with high P. gigivalis load. It also described numerical trends in traditional Alzheimers disease biomarkers, including phosphor-tau 181 and total tau.

Our understanding of the impact of lysine gingipain inhibition on neurodegeneration and other Alzheimers disease markers continues to expand, Michael Detke, MD, Ph.D., Cortexymes chief medical officer, said. The evidence demonstrates our target P. gingivalis may play a key upstream role in both of these areas, and correlations between P. gingivalis biomarkers and clinical assessments show that our ability to inhibit this target potentially leads to improved patient outcomes.

SQZ Biotechnologies Receives $2 Million Grant from NIH for Parkinsons

SQZ Biotech was awarded a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences, a National Institutes of Health division. The two-year grant will support the development of cell engineering approaches to reprogram a patients immune cells directly into dopamine-producing neurons. This will be a potential new therapy for Parkinsons disease, marked by the death of dopamine-producing cells in the brain.

Directly creating dopamine-producing neurons by reprogramming a patients own immune cells would be a major breakthrough and could support a new Parkinsons disease treatment paradigm, Jonathan Gilbert, vice president and head of exploratory research at SQZ Biotechnologies, said. Unlike alternative allogeneic cell replacement approaches in development for Parkinsons disease, by using a patients own cells, treatment might not require chronic immunosuppression. Moreover, in altering cell fate with RNA-based cell engineering methods, no changes to the genome are likely to occur that could carry long-term risks.

The companys Cell Squeeze technology may have broader applications than Parkinsons disease because it is used to induce human pluripotent stem cells to create other cells via delivery of an mRNA encoding for a fate-specifying transcription factor.

Memory T Cells a New Target for Parkinsons Therapies?

Researchers at La Jolla Institute for Allergy and Immunologydiscovered that Parkinsons disease patients have a clear genetic signature of the disease in their memory T cells. Parkinsons disease progresses as dopamine-producing neurons in the brain die, although what is causing the death is unknown. However, one clue is the dead cells contain clumps of the alpha-synuclein protein that has been damaged. Their research found that people with Parkinsons disease have T cells that target alpha-synuclein early in the disease. This suggests a previously undiscovered possibility of an autoimmune component of the disease.

Parkinsons disease is not usually seen as an autoimmune disease, said LJI research assistant Professor Cecilia Lindestam Arlehamn. But all of our work points toward T cells having a role in the disease.

One crucial gene observed in these T cells is LRRK2, which is associated with the familial form of Parkinsons. This opens up potential new targets for treatment and prevention.

New Approach Decreases Brain Damage in PSP, Alzheimers and Related Diseases

Investigators at Washington University School of Medicine in St. Louis demonstrated that targeting astrocytes, specific immune cells in the brain, can reduce tau-related brain damage and inflammation at least in laboratory mice. Dysfunctional astrocytes, whose job is to clean debris out of the brain and repair damage, have been associated with Alzheimers and other neurodegenerative diseases. The researchers identified high levels of Alpha2-NKA, a protein that drives astrocyte toxicity, in brain samples from people who died of progressive supranuclear palsy (PSP), Alzheimers and other tau-related neurodegenerative diseases.

Brain inflammation, in general, is believed to be a contributor to Alzheimers disease, and Gilbert Gallardo, PhD, senior author and an assistant professor of neurology at WU said that inflammation is driven by non-neuronal cells in the brain, including astrocytes. Our study highlights that inflamed astrocytes are contributing to tau-associated pathologies and suggests that suppressing their reactivity may be beneficial in reducing brain inflammation and delaying Alzheimers progression.

The researchers also tested the use of a heart drug, digoxin, which interferes with apha2-NKA activity. The drug worked on mice models of tau-opathies, both when they were beginning to develop tau tangles and when the tangles and damage were already established.

The take-home message here is that suppressing the inflamed astrocytic state halts disease progression, said first author Carolyn Mann, who was then a technician in the Gallardos laboratory. This is important because experimental therapeutics for Alzheimers and related tauopathies have focused largely on clearing pathological proteins that have been implicated in neuronal dysfunction and death. But our study gives evidence that targeting inflamed astrocytes and brain inflammation may be the key to successfully treating such conditions.

Go here to read the rest:
Cortexyme, SQZ, Others Present New Insights into Alzheimer's and Parkinson's - BioSpace

Circulating Tumor Cell Diagnostics Market 2022 Examination and Industry Growth till 2028 The Sabre – The Sabre

The Esticast Research published a Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 Market study report, which has all company profile the key companies and brands, and along with that the report also included a synopsis of market trends, definition, application, and classification. The forecast period 2021-2028is anticipated to be great for the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 market, which will be the face changer for the market. There is a noteworthy rise in export, import, CAGR values, and revenue owing to a continuous surge in users.

The global Circulating Tumor Cell Diagnosis market size is estimated at 26.9 billion USD with a CAGR of 12.9% during the forecasted period from 2021-2028.

Get Exclusive FREE PDF Report Copy :https://www.esticastresearch.com/report/circulating-tumor-cell-diagnostics-market/#request-for-sample

This report by Esticast Research comprises a summary of market definition, opportunities, segmentation, and market trends. In addition, by implementing a prominent technique such as SWOT analysis, the market drivers, restraints, and opportunities are reached.

By Types

By Applications

Browse Full Report Along With Facts and Figurevisit :https://www.esticastresearch.com/report/circulating-tumor-cell-diagnostics-market/

The up surging users day by day, which is increasing import, exports, sales, revenue, export, and CAGR values. Along with the market position, market share, future trends, market dynamics, opportunities, risks, and entry barriers, a complete overview of the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 market is comprised. Several different factors, for example, supply chain, downstream purchasers, and sourcing methodology have been evaluated to give a top to bottom perspective on the market.

The study report includes the market restrictions and drivers, which may be analyzed from a SWOT assessment of the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 market. Major companies and types are taking actions along with stock dispatchers, inclinations, joint endeavors, acquisitions, and forceful research inside the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 market. In the year 2019, a change was seen inside the CAGR ranges are similar to the exchange inside the forecasted year 2021-2028.

The main motto behind this research report is to give a growth map or prospective with respect to activities taken by central members of the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 market like joint endeavors, item dispatches, acquisitions, consolidations, and propensities, which is driving the market and Esticast Research in overall and furthermore impelling the import, business, income, fare and CAGR values.

Download Sample PDF Copy of the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 Market Report to understand structure of the complete report (Including Full TOC, Table & Figures:https://www.esticastresearch.com/report/circulating-tumor-cell-diagnostics-market/#request-for-sample

To distinguish business qualities, Major companies working in the industry have been profiled and recognized. Key companies covered by the report on the global market are:

Thanks for reading this Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 Market report; you can also get individual chapter wise section or region wise report and also Sub-category wise divide the Circulating Tumor Cell Diagnostics Market, By Type (CTC Enrichment, CTC Detection, and CTC Analysis), By Application (Tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others),Industry Analysis, COVID-19 Impact Analysis, Size, Share, Growth, Trends, and Forecasts 2021-2028 market report.

Get More Insight Before Buying or Inquire For Chapter Cost:https://www.esticastresearch.com/report/circulating-tumor-cell-diagnostics-market/#inquiry-before-buying

Note:If you have any special requirement, please let us know and we will offer you the report as you want.

Contact Us:

Mr. Ashish Gedamkar Corporate Sales Specialist Esticast Research USA: +1-213-262-0704 APAC: +91-959-503-5024 Email:ash@esticastresearch.com Visit Our Web Site:www.esticastresearch.com

See original here:
Circulating Tumor Cell Diagnostics Market 2022 Examination and Industry Growth till 2028 The Sabre - The Sabre

SeqLL Announces Formation of Scientific Advisory Board – Yahoo Finance

SeqLL, Inc

BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (SeqLL or the Company) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished and world-renowned leaders of the scientific community. The SAB will discuss with management potential new development opportunities that leverage the Companys unique True Single Molecule Sequencing (tSMS) technology across the omics fields, as well as advise management with their existing collaborative, scientific, & development partnerships. Each leader has previously utilized the tSMS platform and will leverage their expertise to provide valuable insight to our company.

We are privileged to be working with this distinguished and talented group of scientific advisors as we expand the reach of our tSMS technology, said Daniel Jones, CEO, President, and Co-Founder of SeqLL. These advisors bring valuable scientific insight and industry contacts to our work and will assist us in becoming a world-class leader in creating novel assets with our true single molecule sequencing technology.

Leaders of the SeqLL Scientific Advisory Board include:

Claes Wahlestedt, M.D., Ph.D., Chairman of the SAB. Director of the Center for Therapeutic Innovation, Leonard M. Miller School of Medicine, University of Miami. Dr. Wahlestedt has a long-standing academic as well as big pharma career in drug discovery, genomics and epigenetics, and has pioneered various translational efforts in these fields. From 2005 to 2011, Dr. Wahlestedt was a professor and a director at The Scripps Research Institute. Prior to that he founded and ran the genomics and bioinformatics center at the Karolinska Institute (a joint venture with Pharmacia/Pfizer). Among companies he has co-founded are CuRNA (now part of Opko Health/Camp4), based on his patent for targeting regulatory noncoding RNAs to up-regulate therapeutic proteins, and Epigenetix Inc., focusing on small molecule drugs for a variety of drug targets in cancer and neuroscience. He is the author of over 300 papers in scientific journals, with over 45,000 citations. Dr. Wahlestedt is an expert in genomic medicine pertaining to a number of innovative therapeutic modalities and diagnostic approaches.

Story continues

L. Frank Kolakowski, Ph.D., Senior Scientist, Tetracore, Inc. Dr. Kolakowski has a distinguished 30-year scientific research career that includes positions on the faculty of the University of Texas Health Science Center, as an instructor at Harvard Medical School, and as consultant for several U.S. government agencies. As an entrepreneur, Dr. Kolakowski founded and served as CEO of ReceptorBase from 2000-2004, prior to being hired by the prestigious consulting firm Booz Allen Hamilton to initiate and manage their life sciences practice. He received his Doctorate in Chemistry from the University of Pennsylvania and his B.S. in Biology and Chemistry from Towson State University. Tetracore and Dr. Kolakowski are long term partners of SeqLL.

Efrat Shema, Ph.D., Principal Investigator and Assistant Professor at the Weizmann Institute of Science. Recipient of the prestigious Fulbright Scholar, Dr. Shema conducted post-doctoral work under Dr. Bradley Bernstein at Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of MIT and Harvard. During her Ph.D. studies at the Weizmann Institute, Dr. Shema has received multiple prestigious awards, including the Adams Fellowship from the Israel Academy of Sciences and Humanities, the Otto Schwartz Prize for Excellence, and the UNESCO-LOREAL national award for young women in life sciences. Dr. Shema completed her M.Sc. and Ph.D in molecular cell biology at the Weizmann Institute and earned her B.Sc. in life sciences at the Hebrew University in Jerusalem in 2005. Dr. Shemas research has focused on using SeqLLs tSMS platform to decode the cancer epigenome since 2014.

Timothy McCaffrey, Ph.D., Professor of Medicine and Director, Division of Genomic Medicine, George Washington University. Dr. McCaffrey has had a distinguished career in research focused in three major areas: cardiovascular disease, genomics and stem cells. In 2001, he received a prestigious MERIT award from NIH for his work on vascular aging. Dr. McCaffrey is a close collaborator of ours and has used the tSMS platform to identify several panels of RNA transcripts that are highly predictive biomarkers in the fields of cardiovascular disease, infection and inflammation. He co-founded True Bearing Diagnostics to commercialize diagnostics based on those discoveries. He received post-doctoral training at Cornell University Medical College in New York City, his Masters and Doctorate from Purdue University and his B.A. from St. Marys University.

About True Single Molecule Sequencing (tSMS) Technology SeqLLs collaborators are thoroughly committed to using only our tSMS platform in their scientific research due to its unique RNA and DNA sequencing and related services. Our true single molecule sequencing platform is NGS technology offers maximum flexibility and avoids many of the challenges common for standard NGS approaches. It that enables direct sequencing of millions of individual molecules not requiring PCR amplification at any stage of the process and a simple, economical sample prep protocols. Therefore, it captures a precise sample composition, without bias and loss of diversity and rare species. Our tSMS platform is ideally suited for RNA biomarker discovery and diagnostic assay developments, including challenging applications for the standard NGS platform, such as low quantity, difficult or degraded samples of cell-free DNA, FFPE-isolated nucleic acids, ancient DNA and forensic samples.

About SeqLL, Inc. SeqLL Inc. (SeqLL) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The Company leverages its expertise with its True Single Molecule Sequencing (tSMS) platform to empower scientists and researchers with improved genetic tools to better understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with todays precision medicine. In sum, our experienced team works with our collaborators to develop innovative solutions tailored to the needs of each specific project.

Forward Looking Statements This press release contains certain forward-looking statements, including those related to the applicability and viability of the Companys technology to quantifying RNA molecules from blood and other statements that are predictive in nature. Forward-looking statements are based on the Company's current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1, as amended, under the caption "Risk Factors."

Contacts:

Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com

Go here to read the rest:
SeqLL Announces Formation of Scientific Advisory Board - Yahoo Finance

Biologics Safety Testing Market Size And Forecast | Top Key Players Charles River Laboratories International Merck KGaA, Lonza Group Ltd., SGS SA,…

New Jersey, United States,-The latest research report provides a complete assessment of theBiologics Safety TestingMarketfor the forecast year 2022-2029, which is beneficial for businesses regardless of their size and revenue. This survey report covers the key market insights and industry approach related to COVID-19 (Omicron) in the coming years. TheBiologics Safety Testingmarket report provides data and information on the development of the investment structure, technological improvements, market trends and developments, capabilities, and in-depth information on the major players of theBiologics Safety Testingmarket. The market strategies followed worldwide in relation to the current and future scenario of the industry have also been detailed in the study.

The report begins with a brief presentation and overview of theBiologics Safety Testingmarket, the current market landscape, market trends, key market players, product type, application, and region. It also covers the impact of COVID-19 (Omicron) on theBiologics Safety TestingMarket Trends, Future Forecast, Growth Opportunities, End-User Industries, and Market Players. It also provides historical data, current market scenarios, and future insights into the Biologics Safety Testingmarket. This study provides a comprehensive understanding of market value with the product price, demand, gross margin, and supply of theBiologics Safety Testingmarket. The Competitive Perspective section of the report provides a clear insight into the market share analysis of the major players in the industry.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.verifiedmarketresearch.com/download-sample/?rid=24306

Key Players Mentioned in the Biologics Safety Testing Market Research Report:

Charles River Laboratories International Merck KGaA, Lonza Group Ltd., SGS S.A., Thermo Fisher Scientific Inc., Wuxi Apptec, Sartorius AG, Cytovance Biologics, Inc.

The Biologics Safety Testing market is segmented by product and type. All of these segments were examined individually. The detailed study helps to evaluate the factors affecting the Biologics Safety Testing market. Experts analyzed the nature of development, investments in research and development, changing consumption patterns, and the growing number of applications. Furthermore, analysts have also assessed the development of the economy around the Biologics Safety Testing market which is likely to impact its price.

Biologics Safety TestingMarket Segmentation:

Biologics Safety Testing Market by Product and Services

Instruments Services Kits & Reagents

Biologics Safety Testing Market by Application

Vaccine & Therapeutics Development Blood and Blood-Related Product Testing Cellular and Gene Therapy Tissue and Tissue-Related Product Testing Stem Cell Research

Biologics Safety Testing Market by Test Type

Endotoxin Test Sterility Test Cell Line Authentication and Characterization Test Bioburden Test Residual Host Contaminant Detection Test Adventitious Agent Detection Tests Other Test

The regional analysis section of the report allows players to focus on high-growth regions and countries that could help them to expand their presence in the Biologics Safety Testing market. Besides expanding their presence in the Biologics Safety Testing market, regional analysis helps players increase sales while gaining a better understanding of customer behavior in specific regions and countries. The report provides CAGR, revenue, production, consumption, and other important statistics and figures on global and regional markets. It demonstrates how different types, applications, and regional segments of the Biologics Safety Testing market are progressing in terms of growth.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24306

Biologics Safety Testing Market Report Scope

Determining the pulse of the market becomes easy through this in-detail Biologics Safety Testing market analysis. Key players can find all competitive data and market size of major regions like North America, Europe, Latin America, Asia-Pacific and Middle East. As part of the competitive analysis, certain strategies are profiled which are pursued by key players such as mergers, collaborations, acquisitions and new product launches. These strategies will greatly help industry players to strengthen their market position and grow their business.

Key questions answered in the report:

1. Which are the five top players of the Biologics Safety Testing market?

2. How will the Biologics Safety Testing market change in the next five years?

3. Which product and application will take a lions share of the Biologics Safety Testing market?

4. What are the drivers and restraints of the Biologics Safety Testing market?

5. Which regional market will show the highest growth?

6. What will be the CAGR and size of the Biologics Safety Testing market throughout the forecast period?

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/biologics-safety-testing-market/

Visualize Biologics Safety Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Biologics Safety Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080 UK: +44 (753)-715-0008 APAC: +61 (488)-85-9400 US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/

View original post here:
Biologics Safety Testing Market Size And Forecast | Top Key Players Charles River Laboratories International Merck KGaA, Lonza Group Ltd., SGS SA,...